Head to Head Comparison: Endonovo Therapeutics (OTCMKTS:ENDVD) and Spruce Biosciences (NASDAQ:SPRB)

Endonovo Therapeutics (OTCMKTS:ENDVD) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Earnings and Valuation

This table compares Endonovo Therapeutics and Spruce Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A
Spruce Biosciences	N/A	N/A	-$38.97 million	($36.60)	-1.50

Endonovo Therapeutics has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Endonovo Therapeutics and Spruce Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Spruce Biosciences	1	2	7	0	2.60

Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 197.42%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Endonovo Therapeutics.

Risk and Volatility

Endonovo Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500.

Profitability

This table compares Endonovo Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%
Spruce Biosciences	N/A	-155.40%	-101.67%

Summary

Spruce Biosciences beats Endonovo Therapeutics on 7 of the 13 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.